Efficacy News and Research

RSS
NICE decides not to recommend lapatinib for women with advanced breast cancer

NICE decides not to recommend lapatinib for women with advanced breast cancer

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Experts call on international community to commit attention and resources to cervical cancer prevention

Experts call on international community to commit attention and resources to cervical cancer prevention

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen, Elan launch My MS Health, a web-based PRO research program

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.